Clinical Oncology: Case Reports

Opinion

A SCITECHNOL JOURNAL

Advancements in Automated Skin Cancer Detection

Carlos A. Cardenas[1*], Jose Javier Bravo[2]

Introduction

Based in the thriving hub of Miami, Florida, DermaSensor Inc. stands at the forefront of health technology, having recently achieved a groundbreaking milestone in the domain of skin cancer detection [1,2]. Through meticulous research and development, it has successfully concluded two pivotal studies sanctioned by the esteemed Food and Drug Administration (FDA), exceeding all primary endpoints and thereby establishing itself as the exclusive provider of an FDA-cleared, automated skin cancer detection tool in the market [3]. This accomplishment underscores not only the unwavering commitment to revolutionizing early skin cancer detection through advanced imaging and optical technology but also signifies a significant advancement in the fight against this prevalent and potentially life-altering disease [1]. This triumph not only represents a fundamental moment for it but also serves as a testament to the power of innovation and dedication in advancing medical technology and improving patient care, offering hope to countless individuals and relatives affected by skin cancer.

The derma sensor device and breakthrough designation

The DermaSensor device, which received Breakthrough Device Designation from the FDA in 2021, represents a remarkable advancement in aiding Primary Care Physicians (PCPs) in the assessment of skin cancer [1-3]. Leveraging Elastic Scattering Spectroscopy (ESS), a form of optical spectroscopy, the device captures cellular-level information from skin lesions using non-invasive tissue samples and hundreds of wavelengths of light. Its proprietary algorithm promptly evaluates the data, providing results within seconds and eliminating the need for laboratory analysis.

Clinical studies and results

DermaSensor conducted two pivotal studies to evaluate the efficacy of their device [3]. The first study, referred to as DERM-SUCCESS, encompassed over 1,000 patients and was carried out by 22 primary care study centers globally, including the Mayo Clinic [2]. This prospective, blinded study successfully met both of its primary endpoints.

The second pivotal study involved over 100 physicians and demonstrated that the use of the DermaSensor device improved their detection of skin cancer. The study revealed a 96% sensitivity rate across all 224 identified skin cancers [2]. Moreover, a negative result from the device indicated a 97% probability of the lesion being benign. The use of the device reduced the rate of missed skin cancers from 18% to 9%.

***Corresponding author:** Carlos A. Cardenas, Department of Oncology, FORESC (Foundation For Research and Sciences),USA, E-mail: karmed@live.com

Received: February 04, 2024; Manuscript No: COCR-24-128436 **Editor Assigned:** February 10, 2024; PreQC Id: COCR-24-128436(PQ) **Reviewed:** February 16, 2024; QC No: COCR-24-128436(Q) **Revised:** February 18, 2024; Manuscript No: COCR-24-128436(R) **Published:** February 25, 2024; DOI: 10.41723/cocr.7(2).334

In addition to these pivotal studies, DermaSensor also conducted another prospective study titled DERM-ASSESS III, involving 10 dermatology study centers globally [4]. This study enrolled over 500 lesions suspicious for melanoma and demonstrated the device's effectiveness at detecting melanoma while ruling out benign lesions. The results from this study were presented at the American Academy of Dermatology conference in March 2022 [4].

Types of skin cancer detection

The DermaSensor device has demonstrated effectiveness in detecting various types of skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma [4,5]. Its ability to provide rapid and accurate assessments of these different types of skin cancer underscores its potential to significantly enhance early detection and improve patient outcomes.

Challenges and innovations in skin cancer diagnosis

Amidst the backdrop of 5.4 million cases of basal and squamous cell skin cancers diagnosed nearly Every year in the United States , approximately, a significant proportion of skin concerns, are initially assessed by non-specialists, predominantly Primary Care Physicians (PCPs) [6,7]. The inherent lack of specialized training in skin cancer diagnosis among PCPs often necessitates referrals to dermatologists, resulting in potential delays in obtaining definitive diagnoses and specialized care. This delay, in turn, has the potential to impact patient outcomes, particularly in cases where early diagnosis is pivotal for high curability rates. Furthermore, the subsequent need for biopsies of suspicious lesions, coupled with the requirement for pathologist examination, can further prolong the diagnostic process [7]. Moreover, the financial burden on patients arising from inadequate reimbursement by health insurance companies for benign biopsied tissue samples adds to the complexity of the situation.

Conversely, recent advancements in telemedicine and teledermatology present promising avenues to address the aforementioned limitations [8]. Leveraging digital platforms, telemedicine facilitates initial assessments and consultations, potentially circumventing the need for immediate physical referrals and expediting the diagnostic process. Furthermore, the integration of Artificial Intelligence (AI) and machine learning in dermatology has shown potential to enhance diagnostic accuracy, thereby reducing the reliance on invasive biopsies and streamlining the diagnostic pathway [8]. These technological innovations hold the promise of revolutionizing skin cancer diagnosis, offering patients more accessible, efficient, and potentially cost-effective avenues for obtaining timely and accurate care.

Impact on doctors and patients

The DermaSensor device has the potential to revolutionize the diagnosis and management of skin cancer. For doctors, it offers a non-invasive, rapid, and accurate tool that can aid in early detection, leading to timely intervention and improved patient outcomes. With streamlined assessments and immediate results, primary care physicians can make informed decisions during patient consultations, potentially reducing the need for unnecessary referrals to specialists. For patients,

this means quicker assessments, reduced anxiety, and potentially earlier intervention, which could significantly impact treatment outcomes and overall well-being.

Conclusion

The successful completion of pivotal FDA studies represents a significant advancement in the domain of skin cancer detection. The DermaSensor device, leveraging optical spectroscopy and a proprietary algorithm, provides primary care physicians with a non-invasive means to assess skin lesions for potential malignancy. The device's performance in clinical trials has demonstrated encouraging outcomes, enhancing the identification of skin cancer, and reducing instances of overlooked diagnoses. With substantial funding secured, the forthcoming introduction of this innovative skin cancer detection technology in the United States heralds a noteworthy progression in the battle against skin cancer, holding the potential to transform early detection methodologies and enhance patient outcomes.

References

1. DermaSensor Inc. Announces Successful Completion of First Ever FDA Pivotal Studies for Skin Cancer Detection Device for Primary Care. (2024) BioSpace.
2. Kathleen, FDA Approves First AI-Powered Skin Cancer Diagnostic Tool AIM at Melanoma Foundation.
3. FDA Roundup: January 16, 2024 FDA.
4. B. C. M.Sc, DermaSensors: The Future of Skin Cancer Detection News-Medical.
5. Skin Cancer Facts & Statistics, The Skin Cancer Foundation.
6. Basal & Squamous Cell Skin Cancer Statistics.
7. Brown AE, Najmi M, Duke T, Grabell DA, Koshelev MV, et al. (2022). Skin Cancer Education Interventions for Primary Care Providers: A Scoping Review. J Gen Intern Med 37: 2267-2279.
8. Markun S, Scherz N, Rosemann T, Tandjung R, & Braun RP, et al. (2017). Mobile teledermatology for skin cancer screening: a diagnostic accuracy study. Medicine 96.

Author Afiliations Top

[1]*Department of Oncology, FORESC (Foundation For Research and Sciences), USA*

[2]*St. Francis Downtown Hospital, USA.*